欧洲前列腺癌筛查方案的演变及正在进行的试验总结
基于人群的组织性重复筛查可降低前列腺癌特异性死亡率,但过度诊断导致过度治疗。本文综述了筛查、活检指征和治疗环节的多项改进,包括风险个体识别、个体化复检间隔、风险分层活检、靶向活检、主动监测等,这些改进被建议可减少筛查副作用,但缺乏1级证据。欧洲多项前瞻性筛查试验及PRAISE-U项目正在评估这些新方法。
要点
- 基于人群的组织性重复前列腺癌筛查可降低疾病特异性死亡率,但伴随大量过度诊断和过度治疗。
- 现代筛查改进包括风险个体识别、个体化复检间隔、风险分层活检、靶向活检和主动监测等。
- 上述改进被建议可减少筛查副作用并至少维持获益,但缺乏1级证据,正在欧洲前瞻性试验中评估。
核心结论
- 现代筛查方法可能降低欧洲男性第二常见癌症死因的负担,同时最小化副作用,并可能间接减少效果较差的機會性早期检测。
研究设计与样本
- 本文为综述,总结了欧洲前列腺癌筛查方案的演变及正在进行的筛查试验。
- 欧洲多项前瞻性筛查试验正在测试早期检测的新知识和新进展。
- 欧盟资助的PRAISE-U项目将比较和评估欧洲各地不同的筛查试点,并涉及实施与可持续性。
主要发现
- 基于人群的组织性重复筛查可降低前列腺癌特异性死亡率,但伴随大量过度诊断导致过度治疗。
- 只有极少数国家在全国层面实施了筛查规划,但个体PSA检测很普遍,这种機會性检测可能获益有限,同时强调副作用。
- 20世纪90年代的经典早期检测方案采用PSA和直肠指检阈值进行六分区系统前列腺活检,固定复检间隔,且期待管理的指征有限。
- 自这些试验启动以来的三十年间,筛查流程、活检指征和治疗方面出现了多项重要改进。
- 主要改进包括:使用早期/基线PSA、家族史和/或遗传特征更好地识别风险个体;个体化复检间隔;优化和个体化起始与终止年龄,在固定年龄逐步邀请而非邀请更宽的年龄组;使用PSA密度、风险计算器、磁共振成像、血清和尿液生物标志物或其组合/序列进行活检风险分层;靶向活检;经会阴活检路径;低风险前列腺癌的主动监测;以及改进的疾病分期。
关键数值与推荐
- 上述所有改进被建议可减少筛查副作用,同时至少维持获益,但缺乏1级证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 上述改进被建议可减少筛查副作用并至少维持获益,但缺乏1级证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Population-based organised repeated screening for prostate cancer has been found to reduce disease-specific mortality, but with substantial overdiagnosis leading to overtreatment. Although only very few countries have implemented a screening programme on a national level, individual prostate-specific antigen (PSA) testing is common. This opportunistic testing may have little favourable impact, while stressing the side-effects. The classic early detection protocols as were state-of-the-art in the 1990s applied a PSA and digital rectal examination threshold for sextant systematic prostate biopsy, with a fixed interval for re-testing, and limited indication for expectant management. In the three decades since these trials were started, different important improvements have become available in the cascade of screening, indication for biopsy, and treatment. The main developed aspects include: better identification of individuals at risk (using early/baseline PSA, family history, and/or genetic profile), individualised re-testing interval, optimised and individualised starting and stopping age, with gradual invitation at a fixed age rather than invitation of a wider range of age groups, risk stratification for biopsy (using PSA density, risk calculator, magnetic resonance imaging, serum and urine biomarkers, or combinations/sequences), targeted biopsy, transperineal biopsy approach, active surveillance for low-risk prostate cancer, and improved staging of disease. All these developments are suggested to decrease the side-effects of screening, while at least maintaining the advantages, but Level 1 evidence is lacking. The knowledge gained and new developments on early detection are being tested in different prospective screening trials throughout Europe. In addition, the European Union-funded PRostate cancer Awareness and Initiative for Screening in the European Union (PRAISE-U) project will compare and evaluate different screening pilots throughout Europe. Implementation and sustainability will also be addressed. Modern screening approaches may reduce the burden of the second most frequent cause of cancer-related death in European males, while minimising side-effects. Also, less efficacious opportunistic early detection may be indirectly reduced.
引用
- van Harten MJ, Roobol MJ, van Leeuwen PJ, et al. Evolution of European prostate cancer screening protocols and summary of ongoing trials. BJU Int. 2024. PMID: 38469728. doi:10.1111/bju.16311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。